NCIMMUNE LEADING EARLY CANCER DETECTION

See what the media is saying about Oncimmune and early cancer detection.

Date Title Link/PDF
December A blood test for early detection of lung cancer MLO Online A blood test for early detection of lung cancer
December 9 Test detects lung cancer years earlier The Times Test detects lung cancer years earlier
December 9 Simple blood test could show lung cancer 5 years before the disease even appears on medical scans Daily Mail Simple blood test could show lung cancer 5 years before the disease even appears on medical scans
October 1 £220 million for cutting-edge new technology HM Treasury, Gov.uk £220 million for cutting-edge new technology
September 23 Oncimmune shortlisted for Best Technology company in the AIM Awards 2016 Interactive Investor Oncimmune shortlisted for Best Technology company in the AIM Awards 2016
September 22 Oncimmune Notes Asia Focus With Chief Commercial Officer Appointment Morningstar Oncimmune Notes Asia Focus With Chief Commercial Officer Appointment
September 20 Oncimmune Welcomes Study On Effectiveness Of EarlyCDT Platform Morningstar Oncimmune Welcomes Study On Effectiveness Of EarlyCDT Platform
August 23 Are fast diagnostics the key to better healthcare? Investors Chronicle Are fast diagnostics the key to better healthcare?
May 28 Oncimmune's cancer test diagnoses '80pc of tumours' early, saving lives The Telegraph Oncimmune's cancer test diagnoses '80pc of tumours' early, saving lives
April 19 Revolutionary test could save the lives of thousands of smokers Daily Mail Revolutionary test could save the lives of thousands of smokers
April Executive Snapshot, James R Jett MD, Chief Medical Officer, Oncimmune Medical Laboratory Observer Executive Snapshot, James R Jett MD, Chief Medical Officer, Oncimmune
March 23 Oncimmune USA LLC Receives 2016 Best of DeSoto Award DeSoto Award Program Oncimmune USA LLC Receives 2016 Best of DeSoto Award
March 18 Oncimmune Inks Deal With Accu Reference to Offer EarlyCDT®-Lung Test Genomeweb Oncimmune Inks Deal With Accu Reference to Offer EarlyCDT®-Lung Test

PLEASE READ THE FOLLOWING STATEMENT CAREFULLY

Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).

These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.

None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.

By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.

Please click on the button below to confirm that you have read, understood and agree with the disclaimer above.

Yes, I accept No, I don't accept